Infinity Pharmaceuticals Inc (INFI):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10101)・商品コード:DATA904C10101
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:52
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. It is evaluating IPI-549 as a monotherapy in Phase 2 for a solid tumor. Infinity Pharmaceuticals is also investigating IPI-549 in Phase 1 for solid tumors, and in Phase 1B for non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma, adrenocortical carcinoma, and myeloid-derived suppressor cells (MDSC). Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Partnerships 12
Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14
Pharm-Olam International Enters into Agreement with Infinity Pharma 15
Lead Discovery Center Partners with Infinity Pharma 16
Licensing Agreements 17
PellePharm Enters into Licensing Agreement with Infinity Pharma 17
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20
Equity Offering 21
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 24
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 26
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 27
Infinity Pharmaceuticals Inc – Key Competitors 29
Infinity Pharmaceuticals Inc – Key Employees 30
Infinity Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Nov 07, 2018: Bristol-Myers and Infinity partner for trial of opdivo and IPI-549 32
Financial Announcements 33
Nov 05, 2018: Infinity Pharmaceuticals provides company update and third quarter 2018 financial results 33
Aug 07, 2018: Infinity Pharmaceuticals provides company update and second quarter 2018 financial results 35
May 08, 2018: Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results 36
Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 38
Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 40
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 43
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 44
Corporate Communications 46
Aug 07, 2018: Infinity Pharmaceuticals appoints Samuel Agresta as Chief Medical Officer 46
Mar 08, 2018: Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board 47
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 49
Jan 04, 2017: Infinity Announces Organizational Changes 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14
Pharm-Olam International Enters into Agreement with Infinity Pharma 15
Lead Discovery Center Partners with Infinity Pharma 16
PellePharm Enters into Licensing Agreement with Infinity Pharma 17
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 24
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 26
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 27
Infinity Pharmaceuticals Inc, Key Competitors 29
Infinity Pharmaceuticals Inc, Key Employees 30
Infinity Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Infinity Pharmaceuticals Inc (INFI):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10101)販売に関する免責事項を必ずご確認ください。
★調査レポート[Infinity Pharmaceuticals Inc (INFI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆